Plenary 2101: New Paradigms in the Management of Severe Asthma
Clinicians, academicians, fellows-in-training, medical students, basic scientists, Allied Health professionals andpPayers in the field of Allergy/Immunology have the opportunity and challenge of utilizing biologic therapies in research and clinical practice to improve the lives of patients with severe asthma. While biologic therapies continue to become FDA approved, questions remain in the areas of low T2 biologic therapy mechanism of action, use of biomarkers in selection of treatment and monitoring of treatment efficacy for patients with severe asthma, and clinical evidence based algorithms to choose the optimal therapy for patients with severe asthma.
|AAAAI Foundation and K. Frank Austen, MD FAAAAI & Albert L. Sheffer, MD FAAAAI Lectureship: Bench to Bedside||John Fahy, MD||Contemporary Considerations in Targeting Low T2 Components of Asthma|
|AAAAI Foundation and Phillip E. Korenblat, MD FAAAAI Lectureship: Investing Together in Our Future||Sally Wenzel, MD FAAAAI||Contemporary ConsideratiC2:C10ons in Targeting Low T2 Components of Asthma|
|AAAAI Foundation and Dennis K. Ledford, MD FAAAAI & University of South Florida Allergy & Immunology Division Lectureship||Stanley Szefler, MD FAAAAI||An Algorithmic Approach to Selecting and Continuing Biologic Therapy|
- A/I physicians
- A/I fellows-in-training
- A/I nurses, nurse practitioners and physician assistants
Upon completion of this activity, participants should be able to:
- Discuss mechanisms of potential targets of low-T2 phenotypes in asthma
- Identify which biomarkers are most useful, and their specific roles, in the selection of biologic therapies for patients with severe asthma
- Describe an algorithmic approach to the selection and continuation of biologic therapies for the treatment of adult and pediatric patients with severe asthma
John Fahy, MD
University of California San Francisco, San Francisco, CA
Relevant relationships: Ionis Pharmaceuticals, Gossamer (consultant); Boehringer Ingelheim (research grant)
Stanley Szefler, MD FAAAAI
Children's Hospital Colorado, Aurora, CO
Relevant relationships: Regeneron (advisory board)
Sally Wenzel, MD FAAAAI
University of Pittsburgh Medical Center, Pittsburgh, PA
Relevant relationships: Pieris (consultant)
Robert Corriel, MD FAAAAI
Manhasset Allergy and Asthma Associates, Manhasset, NY
Relevant relationships: None
Kara Wada, MD
Nationwide Children’s Hospital, Columbus, OH
Relevant relationships: None
AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:
- Employment. Name of employer and job title.
- Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
- Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
- Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
- Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
- Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
- Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Academy of Allergy, Asthma & Immunology designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Designation Statement
The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 1.25 Contact Hours.
Credit Claiming Period
Credit claiming for this activity will expire at 11:59 pm on April 30, 2022. Requests to claim credit on or after May 1, 2022 will be denied.
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at email@example.com.
Activity-related questions should be directed to firstname.lastname@example.org.
- 1.50 AttendanceAttendance credit.
- 1.50 CECE credit.
- 1.50 CMECME credit.